SLEEP 2025: 7 Late-Breaking Abstracts to Watch

SLEEP 2025, the 39th annual meeting of the Associated Professional Sleep Societies, is less than a week away, taking place in Seattle, Washington, from June 8 – 11th. The meeting is a joint venture of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS).

The conference will feature over 140 exhibits, 1000 abstract presentations, and 150 renowned speakers. From late-breakers and abstracts to keynote addresses and general sessions, attendees can learn about the latest research in sleep medicine.

However, with so much research being presented, studies can fall through the cracks. As a sneak peek of the meeting, HCPLive compiled 7 late-breaker abstracts that you should keep your eye on at the conference.

Presentation: Tuesday, June 10th from 10:00 am – 11:45 am PDT

Location: Exhibit Hall 4E

7 Late-Breaking Abstracts to Watch at SLEEP 2025

LBA 1645 – Nocturnal Spontaneous Arousals in People With Narcolepsy and Idiopathic Hypersomnia Treated With Low-Sodium Oxybate

Presenters: Chad M. Ruoff, MD, David T. Plante, MD, PhD, Deborah A. Nichols, MS, Teresa L. Steininger, PhD, Jing Dai, PhD, M. Todd Kirby, PhD, Sarah Akerman, MD, Jessica K. Alexander, PhD, Alessandra Milesi-Halle, MD, PhD, Logan D. Schneider, MD, Alyssa Cairns, PhD

The phase 4 Jazz DUET trial (NCT05875974) evaluated the effects of low-sodium oxybate (LXB, Xywav®) on polysomnography (PSG)-measured arousals in participants with narcolepsy (type 1 or 2) or idiopathic hypersomnia. The study found patients on low-sodium oxybate had fewer PSG-based spontaneous arousals than at baseline.

LBA 1661 – Vibrance-3: Study Design and Methods for a Phase 2, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Idiopathic Hypersomnia

Presenters: David Plante, Ron Grunstein, Giuseppe Plazzi, Kiran Maski, Jandira Ramos, Yangchun Du, Alexandra Lovett, Marcus Yountz, Bhaskar Rege

The phase 2 trial Vibrance-3 will assess the safety and efficacy of ALKS 2680 over 8 weeks of treatment in patients with idiopathic hypersomnia. This randomized, double-blind, parallel-group study will follow the phase 1b study, which showed dose-dependent improvement in sleep latency.

ALKS 2680 is a highly potent, orally bioavailable, and selective orexin 2 receptor agonist being developed as a once-daily treatment for both narcolepsy and idiopathic hypersomnia. Ongoing trials also explore use in narcolepsy types 1 and 2.

LBA 1669 – Improvement of Sleep Quality and Insomnia Symptoms with Haptic Technology

Presenters: Janet Fason, DO, Paul Doghramji, MD, Peter Hurwitz

RESTORE, a minimal risk, randomized-controlled trial, tested a drug-free haptic vibrotactile trigger technology (VTT) patch (REM Patch) in participants with sleep difficulties. Compared to sham, the active patch improved sleep duration, latency, awakenings, and REM sleep.

LBA 1570 – Electrical Vestibular Nerve Stimulation for PTSD: Does It Improve Insomnia? Findings from a Randomized Controlled Trial

Presenters: Jason McKeown, MD, Peter J. Colvonen, PhD, Joseph Reel, Rachel Robinson, Sinead Watson, PhD

This 12-week RCT evaluated daily 30-minute non-invasive, electrical vestibular nerve stimulation treatment in patients with PTSD. The primary outcome was change in PCL-5 score from baseline to week 12, and the secondary outcome was Insomnia Severity Index at 12 weeks.

LBA 1581 – One-Week of Effective CPAP Treatment Increases the Release of the Incretin Hormone GIP in Patients with OSA and Comorbid Diabetes

Presenters: Eve Van Cauter, Daniela Grimaldi, Guglielmo Beccuti, Babak Mokhlesi

A small proof-of-concept study showed that 1 week of CPAP affected metabolic hormones in patients with type 2 diabetes and OSA. The findings offer insight into a potential link between GIP response and improved outcomes in this population, independent of weight changes.

LBA 1638 –Impact of Benzodiazepine Receptor Agonist Masked Tapering Combined with Augmented CBTI on Daytime Sleepiness and Patient-Reported Sleep Quality

Presenters: Jason Ereso, Cathy Alessi, Jennifer L. Martin, Karen Josephson, Joseph M. Dzierzewski, Alison A. Moore, M. Safwan Badr, Michelle Zeidler, Tue Te, Michael Mitchell, Constance H. Fung

In this randomized trial, older adults tapering off BZRAs via masked tapering combined with augmented CBTI (MTcap) or supervised gradual taper (SGT) saw improvements in sleepiness and sleep quality. MTcap had greater discontinuation rates at 6 months, but sleep outcomes were similar due to CBTI's presence in both arms.

LBA 1663 –Rapid Efficacy of a Non-Pharmacological Auditory Biofeedback Digital Therapeutic for Insomnia: A Randomized Crossover Proof-of-Concept Trial

Presenters: Jonghwa Jeonglok Park, Jiyeon Ha, Jae Eun Lee, Mangyeong Lee, Juhee Cho, Da-Mee Kim, Sungkyu Yu, Ho-Jin Lee, and Ki-Young Jung

In a randomized crossover proof-of-concept trial, SAB Therapy, a mobile-based auditory biofeedback digital therapeutic, improved sleep latency, efficiency, deep sleep, and reduced wake after sleep onset. The non-pharmacological tool shows promise as an accessible insomnia treatment.